Phaseline

Companies › JCR Pharmaceuticals

JCR Pharmaceuticals: clinical trials, targets and expected readouts

3 active drug programs in 6 registered trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pabinafusp Alfa (JR-141)
Transferrin receptor binding agent
TFRC, TFR2Phase 3Mucopolysaccharidosis IIDec 2026
JR-446
Gene therapy for mucopolysaccharidosis type IIIB
–Phase 1Mucopolysaccharidosis IIIB; Mucopolysaccharidosis III-BJun 2028
JR-441 (posnafusp alfa)
Recombinant N-acetyl-alpha-glucosaminidase (NAGLU) enzyme replacement therapy
NAGLUPhase 1Mucopolysaccharidosis III-AOct 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03708965Pabinafusp Alfa (JR-141)Phase 2Mucopolysaccharidosis IIMetabolic and endocrineDec 2026
NCT04573023Pabinafusp Alfa (JR-141)Phase 3Mucopolysaccharidosis IIMetabolic and endocrineOct 2027
NCT07640984JR-446Phase 1Mucopolysaccharidosis IIIBMetabolic and endocrineJun 2028
NCT06095388JR-441 (posnafusp alfa)Phase 1Mucopolysaccharidosis III-AMetabolic and endocrineOct 2029
NCT04348136Pabinafusp Alfa (JR-141)Phase 2Mucopolysaccharidosis IIMetabolic and endocrineMar 2030
NCT06488924JR-446Phase 1Mucopolysaccharidosis III-BMetabolic and endocrineApr 2030

Targets

TFRC (1) TFR2 (1) NAGLU (1)

Companies with the same targets

Halia Therapeutics

Companies built like this

Ascletis Pharma (China) Laekna The United Bio-Technology (Hengqin) BrightGene Bio-Medical Technology Biomea Fusion

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.